Phase II PATHWay: adjuvant pembrolizumab in patients with HNSC cancer at high risk for recurrence

Shloma Koyfman, MD, Cleveland Clinic, Cleveland, OH, discusses findings from the PATHWay trial (NCT02841748), evaluating pembrolizumab's adjuvant use in high-risk head/neck squamous cell carcinoma post-curative treatment. Pembrolizumab demonstrated superior progression-free survival (PFS) compared to placebo. Notably, PFS benefits extended to subgroups like salvage surgery recipients and those with multiple recurrences/primaries. Overall survival (OS) didn't differ significantly. Adverse events were comparable. Pembrolizumab's adjuvant use shows promise in reducing recurrence risk. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.